论文部分内容阅读
丙戊酸钠(VPA;商品名:德巴金)于1976年被应用于临床,因其疗效肯定,近年来被用于临床首选广谱抗癫痫及预防用药,其在颅脑损伤后预防癫痫、癫痫外科、颅脑手术后和控制癫痫发作中的作用不断得到重视。其严重的不良反应有肝毒性、胰腺炎、血小板减少等[1、2]。首例丙戊酸钠致高氨血症及丙戊酸钠脑病由Coulter等[3]于1980年首先报道,发生于1例儿童癫痫患者。近日我科偶然出现1例丙戊酸钠致高氨血症
Sodium valproate (VPA; trade name: De Ba Jin) was applied to clinical in 1976, because of its efficacy, in recent years has been used for clinical choice of broad-spectrum anti-epilepsy and prophylaxis, the prevention of epilepsy after traumatic brain injury, The role of epilepsy surgery, craniocerebral surgery and control of seizures continue to receive attention. The serious side effects of liver toxicity, pancreatitis, thrombocytopenia [1,2]. The first sodium valproate-induced hyperammonemia and valproate encephalopathy was first reported by Coulter et al [3] in 1980 and occurred in 1 patient with epilepsy in childhood. Recently, a case of sodium valproate caused hypernatremia in our department